News | March 06, 2021
Sun Pharma arm to acquire stake in WRS Bioproducts, Australia
The consideration to be paid will be AUD 2.0 mn for 12.5% stake.
The consideration to be paid will be AUD 2.0 mn for 12.5% stake.
Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.
The new functionality complements Parse’s existing Evercode immune products
The approval expands the drug’s existing COPD indication, making it the only single-inhaler triple therapy (SITT) available for both respiratory conditions in China
The collaboration will center on expanding access to Eastman’s Esmeri technology
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
The approval is grounded in data from a Phase III randomized, double-blind, placebo-controlled, crossover study in NPC patients
A PhD in Pharmaceutical Sciences, Dr Singh has led global regulatory audits, product validations, and quality systems spanning therapeutic formulations, dietary supplements, and functional foods
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
Subscribe To Our Newsletter & Stay Updated
